BioWorld Asia

Aug. 18, 2010

New Agent Boosts Prospects for Photodynamic Therapy

Genetic Testing Guidelines Offer Common Principles

Mayo Clinic, Cardio3 Report on Heart Failure Therapy

Other News To Note

PregLem In-Licenses Merck Serona's Jun Kinase Inhibitor

PregLem SA is in-licensing an oral, preclinical Jun kinase inhibitor, bentamapimod (AS602801), from Merck Serono SA, for prevention of postsurgical abdominal adhesions and endometriosis in patients. (BioWorld International) Read More

Angels Fly in When Funds Dry up From VCs, Banks

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...